Evidence map›Paper›PMID 29207055›Full record

ArticleInternational journal of molecular medicine2018

Therapeutic effects of conditioned medium from bone marrow-derived mesenchymal stem cells on epithelial-mesenchymal transition in A549 cells.

Xin Wang, Jun-Ling Gao, Man-Man Zhao, Hui-Xing Zhu, Yan-Xia Tian, Ran Li, Xiao-Hua Jiang, Lei Yu, Jing-Rui Tian, Jian-Zhong Cui

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xin WangSchool of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China.
Jun-Ling GaoSchool of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China.
Man-Man ZhaoSchool of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China.
Hui-Xing ZhuSchool of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China.
Yan-Xia TianSchool of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China.
Ran LiSchool of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China.
Xiao-Hua JiangSchool of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China.
Lei YuSchool of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China.
Jing-Rui TianSchool of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China.
Jian-Zhong CuiDepartment of Neurosurgery, Tangshan Workers' Hospital, Tangshan, Hebei 063000, P.R. China.
North China University of Science and Technology · CNLiaoning Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis (PF) is a chronic lung disease. The transforming growth factor-β1 (TGF-β1)/Smad3 signaling pathway plays an important role in the pathogenesis of pulmonary fibrosis. Bone marrow-derived mesenchymal stem cells (BMSCs) have been shown to be a modulator of the molecular aspects of the fibrosis pathway. However, it is still unknown as to whether the conditioned medium from BMSCs (BMSCs-CM) inhibits the epithelial-mesenchymal transition (EMT) process. This study confirmed the hypothesis that BMSCs-CM exerts an anti-fibrotic effect on human type II alveolar epithelial cells (A549) by suppressing the phosphorylation of Smad3. We used the A549 cells in vitro to detect morphological evidence of EMT by phase-contrast microscopy. These cells were randomly divided into 4 groups as follows: the control group, the TGF-β1 group, the SIS3 (specific inhibitor of Smad3) group and the BMSCs-CM group. The immunofluorescence method was used to determined the location of E-cadherin (E-calcium mucins; E-cad), α-smooth muscle actin (α-SMA) and p-Smad3. The expression levels of E-cad, CK8, α-SMA, vimentin, p-Smad3, Snail1, collagen I (COLI) and collagen III (COLIII) were detected by western blot analysis. Following exposure to TGF-β1, the A549 cells displayed a spindle-shaped fibroblast-like morphology. In accordance with these morphological changes, the expression levels of E-cad and CK8 were downregulated, while the expression levels of α-SMA and vimentin were upregulated. Along with this process, the expression levels of p-Smad3, Snail1, COLI and COLIII were increased. However, the cells in the BMSCs-CM group and SIS3 group exhibited a decrease in the levels of α-SMA and vimentin (which had been upregulated by TGF-β1), and an increase in the levels of E-cad and CK8 expression (which had been downregulated by TGF-β1). On the whole, these results indicated that BMSCs-CM suppressed the EMT which might be associated with TGF-β1/Smad3. This study provides the theoretical basis for the research of the mechanisms responsible for pulmonary disease.

Indexed as

A549 CellsActinsBone Marrow CellsCadherinsCulture Media, ConditionedEpithelial-Mesenchymal TransitionGene Expression RegulationHumansIsoquinolinesMesenchymal Stem CellsPulmonary FibrosisPyridinesPyrrolesSmad3 ProteinTransforming Growth Factor beta16,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochlorideACTA2 protein, humanActinsCadherinsCulture Media, ConditionedIsoquinolinesPyridinesPyrrolesSmad3 ProteinTGFB1 protein, humanTransforming Growth Factor beta1

Identifiers

PMID29207055
PMCPMC5752235
OpenAlexW2770507335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.